tirzepatide psychiatric side effects A recent post hoc analysis published in Obesity found vs. placebo was not associated with increased risk of depression symptoms. Rates of suicidal ideation and behavior were low and similar to Tirzepatide Side Effects: Risks, Safety,

The Obesity Trial An earlier, separate Phase 2 trial in a non-diabetic obesity population reported weight loss up to 22% over 36 weeks the result that led Novo Nordisk to advance zenagamtide into Phase 3 obesity development, which began enrolling in early 2026

- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Every year, innovators rush into GLP studies before they're truly ready

Heres a general overview for single-use semaglutide pens: Wash your hands thoroughly

A 27-gauge, 5/8-inch needle works for most patients